Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma

Muhammad A. Mir, Matthew J. Maurer, Steven C. Ziesmer, Susan L Slager, Thomas Matthew Habermann, William R. Macon, Brian K. Link, Sergei Syrbu, Thomas Elmer Witzig, Jonathan W. Friedberg, Oliver Press, Michael LeBlanc, James R Cerhan, Anne J Novak, Stephen Maxted Ansell

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Serum cytokines and chemokines may reflect tumor biology and host response in follicular lymphoma (FL). To determine whether the addition of these biological factors may further refine prognostication, 30 cytokines and chemokines were measured in pretreatment serum specimens from newly diagnosed FL patients(n = 209) and from 400 matched controls. Cytokine levels were correlated with clinical outcome in patients who were observed or received single agent rituximab, or those who received chemotherapy. Correlations with outcome in chemotherapy treated patients were further examined in a separate cohort of 183 South West Oncology Group(SWOG) patients and all patients were then included in a meta-analysis. Six cytokines were associated with outcome in the Molecular Epidemiology Resource (MER) after adjusting for the FL international prognostic index. In patients who were observed or treated with rituximab alone, increased serum IL-12 and interleukin 1 receptor antagonist(IL-1RA)(P = .005 and .02) were associated with a shorter event-free survival. In patients receiving chemotherapy, hepatocyte growth factor, IL-8, IL-1RA, and CXCL9 (P5.015, .048, .004, and .0005) predicted a shorter EFS. When the MER chemotherapy treated patients and SWOG patients were combined in a meta-analysis, IL-2R, IL-1RA, and CXCL9 (P 5.013, .042, and .0012) were associated with a poor EFS.

Original languageEnglish (US)
Pages (from-to)992-998
Number of pages7
JournalBlood
Volume125
Issue number6
DOIs
StatePublished - Feb 5 2015

Fingerprint

Follicular Lymphoma
Chemotherapy
Interleukin-1 Receptors
Cytokines
Oncology
Serum
Chemokines
Hepatocyte Growth Factor
Drug Therapy
Biological Factors
Interleukin-12
Molecular Epidemiology
Interleukin-8
Tumors
Meta-Analysis
Disease-Free Survival
Rituximab

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. / Mir, Muhammad A.; Maurer, Matthew J.; Ziesmer, Steven C.; Slager, Susan L; Habermann, Thomas Matthew; Macon, William R.; Link, Brian K.; Syrbu, Sergei; Witzig, Thomas Elmer; Friedberg, Jonathan W.; Press, Oliver; LeBlanc, Michael; Cerhan, James R; Novak, Anne J; Ansell, Stephen Maxted.

In: Blood, Vol. 125, No. 6, 05.02.2015, p. 992-998.

Research output: Contribution to journalArticle

Mir, Muhammad A. ; Maurer, Matthew J. ; Ziesmer, Steven C. ; Slager, Susan L ; Habermann, Thomas Matthew ; Macon, William R. ; Link, Brian K. ; Syrbu, Sergei ; Witzig, Thomas Elmer ; Friedberg, Jonathan W. ; Press, Oliver ; LeBlanc, Michael ; Cerhan, James R ; Novak, Anne J ; Ansell, Stephen Maxted. / Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. In: Blood. 2015 ; Vol. 125, No. 6. pp. 992-998.
@article{b8467801b2e54bce80d01e4236af5845,
title = "Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma",
abstract = "Serum cytokines and chemokines may reflect tumor biology and host response in follicular lymphoma (FL). To determine whether the addition of these biological factors may further refine prognostication, 30 cytokines and chemokines were measured in pretreatment serum specimens from newly diagnosed FL patients(n = 209) and from 400 matched controls. Cytokine levels were correlated with clinical outcome in patients who were observed or received single agent rituximab, or those who received chemotherapy. Correlations with outcome in chemotherapy treated patients were further examined in a separate cohort of 183 South West Oncology Group(SWOG) patients and all patients were then included in a meta-analysis. Six cytokines were associated with outcome in the Molecular Epidemiology Resource (MER) after adjusting for the FL international prognostic index. In patients who were observed or treated with rituximab alone, increased serum IL-12 and interleukin 1 receptor antagonist(IL-1RA)(P = .005 and .02) were associated with a shorter event-free survival. In patients receiving chemotherapy, hepatocyte growth factor, IL-8, IL-1RA, and CXCL9 (P5.015, .048, .004, and .0005) predicted a shorter EFS. When the MER chemotherapy treated patients and SWOG patients were combined in a meta-analysis, IL-2R, IL-1RA, and CXCL9 (P 5.013, .042, and .0012) were associated with a poor EFS.",
author = "Mir, {Muhammad A.} and Maurer, {Matthew J.} and Ziesmer, {Steven C.} and Slager, {Susan L} and Habermann, {Thomas Matthew} and Macon, {William R.} and Link, {Brian K.} and Sergei Syrbu and Witzig, {Thomas Elmer} and Friedberg, {Jonathan W.} and Oliver Press and Michael LeBlanc and Cerhan, {James R} and Novak, {Anne J} and Ansell, {Stephen Maxted}",
year = "2015",
month = "2",
day = "5",
doi = "10.1182/blood-2014-06-583369",
language = "English (US)",
volume = "125",
pages = "992--998",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma

AU - Mir, Muhammad A.

AU - Maurer, Matthew J.

AU - Ziesmer, Steven C.

AU - Slager, Susan L

AU - Habermann, Thomas Matthew

AU - Macon, William R.

AU - Link, Brian K.

AU - Syrbu, Sergei

AU - Witzig, Thomas Elmer

AU - Friedberg, Jonathan W.

AU - Press, Oliver

AU - LeBlanc, Michael

AU - Cerhan, James R

AU - Novak, Anne J

AU - Ansell, Stephen Maxted

PY - 2015/2/5

Y1 - 2015/2/5

N2 - Serum cytokines and chemokines may reflect tumor biology and host response in follicular lymphoma (FL). To determine whether the addition of these biological factors may further refine prognostication, 30 cytokines and chemokines were measured in pretreatment serum specimens from newly diagnosed FL patients(n = 209) and from 400 matched controls. Cytokine levels were correlated with clinical outcome in patients who were observed or received single agent rituximab, or those who received chemotherapy. Correlations with outcome in chemotherapy treated patients were further examined in a separate cohort of 183 South West Oncology Group(SWOG) patients and all patients were then included in a meta-analysis. Six cytokines were associated with outcome in the Molecular Epidemiology Resource (MER) after adjusting for the FL international prognostic index. In patients who were observed or treated with rituximab alone, increased serum IL-12 and interleukin 1 receptor antagonist(IL-1RA)(P = .005 and .02) were associated with a shorter event-free survival. In patients receiving chemotherapy, hepatocyte growth factor, IL-8, IL-1RA, and CXCL9 (P5.015, .048, .004, and .0005) predicted a shorter EFS. When the MER chemotherapy treated patients and SWOG patients were combined in a meta-analysis, IL-2R, IL-1RA, and CXCL9 (P 5.013, .042, and .0012) were associated with a poor EFS.

AB - Serum cytokines and chemokines may reflect tumor biology and host response in follicular lymphoma (FL). To determine whether the addition of these biological factors may further refine prognostication, 30 cytokines and chemokines were measured in pretreatment serum specimens from newly diagnosed FL patients(n = 209) and from 400 matched controls. Cytokine levels were correlated with clinical outcome in patients who were observed or received single agent rituximab, or those who received chemotherapy. Correlations with outcome in chemotherapy treated patients were further examined in a separate cohort of 183 South West Oncology Group(SWOG) patients and all patients were then included in a meta-analysis. Six cytokines were associated with outcome in the Molecular Epidemiology Resource (MER) after adjusting for the FL international prognostic index. In patients who were observed or treated with rituximab alone, increased serum IL-12 and interleukin 1 receptor antagonist(IL-1RA)(P = .005 and .02) were associated with a shorter event-free survival. In patients receiving chemotherapy, hepatocyte growth factor, IL-8, IL-1RA, and CXCL9 (P5.015, .048, .004, and .0005) predicted a shorter EFS. When the MER chemotherapy treated patients and SWOG patients were combined in a meta-analysis, IL-2R, IL-1RA, and CXCL9 (P 5.013, .042, and .0012) were associated with a poor EFS.

UR - http://www.scopus.com/inward/record.url?scp=84922358591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922358591&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-06-583369

DO - 10.1182/blood-2014-06-583369

M3 - Article

C2 - 25422100

AN - SCOPUS:84922358591

VL - 125

SP - 992

EP - 998

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -